Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Stella Pharma's Pre-Tax Income for the
six
months ended in Mar. 2026 was 円-471.5 Mil. Stella Pharma's Revenue for the
six
months ended in Mar. 2026 was 円123.2 Mil. Therefore, Stella Pharma's pretax margin for the quarter that ended in Mar. 2026 was -382.76%.
The historical rank and industry rank for Stella Pharma's Pretax Margin % or its related term are showing as below:
TSE:4888'
s Pretax Margin % Range Over the Past 10 Years
Min: -763.36 Med: -300.54 Max: -14.35
Current: -240.58
TSE:4888's Pretax Margin % is ranked worse than 62.27% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs TSE:4888: -240.58
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Stella Pharma Pretax Margin % Related Terms
Stella Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Stella Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4888 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Stella Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Stella Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stella Pharma (TSE:4888) has a Pretax Margin % of -382.76% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stella Pharma and its competitors. According to the industry distribution chart, Stella Pharma ranks #586 out of 941 companies in the Biotechnology industry, placing it in the top 62.3%.
Is Stella Pharma's Pretax Margin % too high?
Stella Pharma's current Pretax Margin % is -382.76%. Based on the distribution chart, Stella Pharma ranks #586 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #586 out of 941 companies for Pretax Margin %. This places Stella Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stella Pharma and its competitors. Stella Pharma's current Pretax Margin % is -382.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.87, compared to a current price of 円337.00 — trading 0.3% below its estimated fair value. The current Pretax Margin % is -382.76%. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Pretax Margin % is -382.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円337.00 is trading 0.3% below its estimated GF Value™ of 円337.87.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
Pretax Margin %: -382.76%
GF Value™: 円337.87 vs. price of 円337.00 (0.3% below fair value)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score
Get the complete analysis for TSE:4888
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
